<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01066429</url>
  </required_header>
  <id_info>
    <org_study_id>DA-EDOCH14-R/07</org_study_id>
    <nct_id>NCT01066429</nct_id>
  </id_info>
  <brief_title>DA-EDOCH14-R in Poor-prognosis Diffuse Large B-cell Lymphoma</brief_title>
  <official_title>Treatment With Infusional Dose-adjusted Etoposide/Vincristine/Doxorubicin/Bolus Cyclophosphamide/Dexamethasone and Rituximab (DA-EDOCH14-R) in Patients With Poor-prognosis Diffuse Large B-cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitario Principe de Asturias</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitario Principe de Asturias</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Poor prognosis dufuse large B-cell lymphoma (DLBCL) represents 50% of all DLBCL with overall
      cure rates ranging from 50-60% with modern dose-dense immunochemotherapy regimens such as
      R-CHOP14. Using an alternative strategy, as infusional and dose-adjusted R-EPOCH, the
      investigators have shown an 83% of complete responses (CR), with an estimated 5-year overall
      survival (OS) rate of 75% (García-Suárez et al. British Journal of Haematology 2007,
      136:276). Despite this improvement in outcome, the search for new treatment strategies should
      continue. Therefore, compared with prior R-EPOCH the investigators decided to investigate
      whether the introduction of dexamethasone (40 mg IV on days 1-5) in place of prednisone
      (based upon data which demonstrated that the former was associated with enhanced Central
      Nervious System penetration) and the reduction of treatment intervals from 3 to 2 weeks would
      be feasible and might improve the outcome in this group of patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Medication, Dose and Method for Administration:

        -  Rituximab: 375 mg/m2, endovenous, according to the protocol of the service, day 1
           (except in the first cycle, in which it will be on day 5).

        -  Etoposide: 50 mg/m2/day, in continuous 24-hour infusion, days 1 to 4.

        -  Adriamycin: 10 mg/m2/day, in continuous 24-hour infusion of, days 1 to 4.

        -  Vincristine: 0.4 mg/m2/day, in continuous 24-hour infusion, days 1 to 4

        -  Dexamethasone: 40 mg, endovenous, days 1 to 5. Followed by prednisone 30 mg (day +6), 20
           mg (day +7), and 10 mg (day +8).

        -  Cyclophosphamide: 750 mg/m2, endovenous, in 30 minutes, day 5, after ending the
           continuous infusion of adriamycin, etoposide and vincristine.

        -  MESNA (If the dose of Cyclophosphamide is &gt; 1 g/m2
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2009</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>efficacy of the EDOCH14-R scheme at an adjusted dose</measure>
    <time_frame>Between December 2009 and January 2012</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>hematological and extra-hematological toxicity of the EDOCH14-R scheme</measure>
    <time_frame>Between december 2009 and January 2012</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Diffuse Large B-Cell Lymphoma (DLBCL)</condition>
  <arm_group>
    <arm_group_label>Poor prognosis DLBCL</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Newly diagnosed patients with DLBCL and an age-adjusted IPI 2-3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone and dose-dense immunochemoterapy</intervention_name>
    <description>Administration every 14 days of the EDOCH-R scheme.</description>
    <arm_group_label>Poor prognosis DLBCL</arm_group_label>
    <other_name>Dose-dense therapy</other_name>
    <other_name>Rituximab</other_name>
    <other_name>dexamethasone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signing the Informed Consent.

          -  Histology: diffuse large B-cell lymphoma de novo (primary mediastinal B-cell lymphomas
             will be included provided that they have a mass greater than 7 cm in larger diameter)
             and follicular NHL grade 3b.

          -  aaIPI: 2-3.

          -  Age: Between 18 and 70 years.

          -  General Condition (ECOG/WHO): Proper organic function, defined by: FEVI ≥ 40%, serum
             creatinine &lt; 150 µmol/L, serum bilirubin &lt; 30 µmol/L, control of other medical
             conditions such as: infection, leukocytes ≥ 3.5 x 109/l and platelets ≥ 100 x 109/l
             (except if they are caused by lymphomatous infiltration of bone marrow or of the
             spleen).

        Exclusion Criteria:

          -  HIV-positive.

          -  Pregnancy or breastfeeding.

          -  Serious disease compromising the performance of the therapeutic regimen.

          -  Recent history of another malignant disease (except skin cancer different from
             melanoma or carcinoma in-situ of the cervix), prior radiotherapy or chemotherapy,
             history of indolent lymphoma.

          -  CNS infiltration at diagnosis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julio Garcia-Suarez, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service of Hematology, Principe de Asturias University Hospital,</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julio Garcia-Suarez, MD, PhD</last_name>
    <phone>34-91-8878100</phone>
    <phone_ext>2099</phone_ext>
    <email>jgarciasu.hupa@salud.madrid.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Principe de Asturias University Hospital</name>
      <address>
        <city>Alcala de Henares</city>
        <state>Madrid</state>
        <zip>28805</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julio Garcia-Suarez, MD, PhD</last_name>
      <phone>34-91-8878100</phone>
      <phone_ext>2099</phone_ext>
      <email>jgarciasu.hupa@salud.madrid.org</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 8, 2010</study_first_submitted>
  <study_first_submitted_qc>February 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2010</study_first_posted>
  <last_update_submitted>February 11, 2010</last_update_submitted>
  <last_update_submitted_qc>February 11, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 12, 2010</last_update_posted>
  <responsible_party>
    <name_title>Hematology Service</name_title>
    <organization>Hospital Principe de Asturias</organization>
  </responsible_party>
  <keyword>poor-prognosis diffuse large B-cell lymphoma</keyword>
  <keyword>dose-adjusted</keyword>
  <keyword>R-EDOCH-14</keyword>
  <keyword>rituximab</keyword>
  <keyword>age-adjusted IPI</keyword>
  <keyword>toxicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

